$NVO

Trump administration preparing 100% tariffs on pharmaceutical companies refusing pricing deals, with major drugmakers already securing three-year reprieves through MFN agreements.

Eli Lilly stock surged 4% after FDA approval of Foundayo, its oral weight-loss pill priced at $149/month, competing with Novo Nordisk's Wegovy.

Novo Nordisk launches Wegovy subscription program with monthly pricing from $249-$329, offering up to $1,200 annual savings via telehealth partners.

American Heart Association launches Cardiovascular-Kidney-Metabolic initiative to address interconnected diseases affecting 90% of U.S. adults, emphasizing screening and prevention.

Pfizer pursues GLP-1 market opportunity through acquisition after internal failure, offering 6.2% dividend yield amid 50% stock decline from 2021 peaks.

Viking Therapeutics' VK2735 could threaten Novo Nordisk and Eli Lilly's GLP-1 dominance if phase 3 trials succeed, triggering potential threefold gains or severe losses.

Novo Nordisk wins FDA approval for Awiqli, the first once-weekly basal insulin for Type 2 diabetes, potentially improving patient adherence and capturing significant market share.

FDA approves Novo Nordisk's Awiqli, the first once-weekly basal insulin for type 2 diabetes, launching in US during second half 2026 based on successful ONWARDS trials.

$LLY dominates GLP-1 market with strong Mounjaro, Zepbound sales but trades at 40x P/E—well above pharma peers—raising concerns about priced-in perfection.

Novo Nordisk and United Biotechnology's experimental drug UBT251 outperformed semaglutide in phase 2 trials, delivering stronger weight loss and glucose control.

U.S. stock futures surge over 1% despite Iran tensions. Robinhood, Arm Holdings, and Circle Internet Group lead gainers.

iDEL Therapeutics appoints Dr. Claudia Ulbrich as Board Chair and secures €9M seed funding led by BiomedVC to advance its novel cancer drug delivery platform.

Over 40 Indian pharma companies launched generic semaglutide after patent expiration, pricing treatments 70% below Novo Nordisk's originals. Market expansion planned globally.

Eli Lilly awaits April 10 FDA decision on oral weight loss drug orforglipron, amid $11B quarterly sales from current portfolio. Approval could catalyze gains, but long-term fundamentals matter more than short-term decisions.

Novo Nordisk wins FDA approval for Wegovy HD, a higher-dose version launching in April across 70,000+ U.S. pharmacies, despite modest stock decline.

Eli Lilly's GLP-1 drugs drive 56% of revenues with explosive growth, but 43x P/E valuation leaves no room for disappointment amid intensifying competition and future patent risks.

Three healthcare stocks under $50 offer distinct value: Pfizer at $27.45 with 9x P/E and strong oncology pipeline; Novo Nordisk at $38.43 capitalizing on weight-loss drugs; Exelixis at $41.80 with proven oncology franchise.

Eli Lilly dominates weight loss drugs with 60% U.S. market share and triple-digit growth, while Viking Therapeutics advances competitive VK2735. Lilly's 8% YTD decline and 28x forward earnings may offer value.

HSBC downgraded $LLY to Reduce, citing inflated obesity market projections. The analyst sees $80-120B market by 2032, not Wall Street's $150B estimate.

Portnoy Law Firm investigates Novo Nordisk for possible securities fraud after CagriSema obesity drug failed trial, triggering 16.43% stock decline.